NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

NCT01098266 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Pleural Mesothelioma

Interventions

DRUG: NGR-hTNF plus Best Investigator's Choice (BIC)
DRUG: Placebo plus Best Investigator's Choice (BIC)

Sponsor

AGC Biologics S.p.A.